The Ribeiro Pereira Lab centers on preclinical multimodal imaging to determine biological mechanisms by which some tumors do not respond to and/or develop resistance to cancer therapies. We then modulate tumor biology with the aim to convert non-responder tumors into responders. Our group has four major goals:

  • Use biomolecules, ranging from small molecules to full-length antibodies, as tumor-targeting agents to deliver imaging or cytotoxic cargo
  • Use multimodal imaging to monitor the binding of molecular-targeted compounds to tumors before and during therapy
  • Use acute and temporal pharmacologic approaches to modulate tumor biology in ways that enhance tumor binding of antibody- and non-antibody-based cancer therapies
  • Improve cancer diagnosis and treatment by combining basic tumor biology with preclinical knowledge and clinical needs